INTEGRATE IIa Phase III Study: Regorafenib for Refractory Advanced Gastric Cancer.

MLA

Pavlakis, Nick, et al. “INTEGRATE IIa Phase III Study: Regorafenib for Refractory Advanced Gastric Cancer.” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, Oct. 2024, p. JCO2400055. EBSCOhost, https://doi.org/10.1200/JCO.24.00055.

APA

Pavlakis, N., Shitara, K., Sjoquist, K., Martin, A., Jaworski, A., Tebbutt, N., Bang, Y.-J., Alcindor, T., O’Callaghan, C., Strickland, A., Rha, S. Y., Lee, K.-W., Kim, J.-S., Bai, L.-Y., Hara, H., Oh, D.-Y., Yip, S., Zalcberg, J., Price, T., … Goldstein, D. (2024). INTEGRATE IIa Phase III Study: Regorafenib for Refractory Advanced Gastric Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, JCO2400055. https://doi.org/10.1200/JCO.24.00055

Chicago

Pavlakis, Nick, Kohei Shitara, Katrin Sjoquist, Andrew Martin, Anthony Jaworski, Niall Tebbutt, Yung-Jue Bang, et al. 2024. “INTEGRATE IIa Phase III Study: Regorafenib for Refractory Advanced Gastric Cancer.” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, October, JCO2400055. doi:10.1200/JCO.24.00055.